Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...

View Bio-Rad Laboratories, Inc. Class A BIO stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

On Wednesday, Bio-Rad Labs ABIO got an upgrade to its Relative Strength (RS) Rating, from 69 to 72. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The Day How ...

Activist investor Elliott Investment Management has built a sizable stake in Bio-Rad Laboratories to boost the firm’s underperforming stock price, the Wall Street Journal reported, citing people ...

We recently published a list of Billionaire Mason Hawkins’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) ...

Elliott reportedly built a sizable Bio-Rad stake as the life-science tools supplier trades far below its late-2021 peak.

At its April 21, 2026 annual meeting of stockholders, Bio-Rad Laboratories, Inc. reported that all nominated directors were elected by majorities within their respective classes of common stock, ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.